The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study
Open accessAbstract
Purpose: The optimal therapeutic sequence of the adjuvant chemotherapy component of preoperative chemoradiotherapy (CRT) for patients with locally advanced rectal cancer is controversial. Induction chemotherapy before preoperative CRT may be associated with better efficacy and compliance. Patients and Methods: A total of 108 patients with locally advanced rectal cancer were randomly assigned to arm A—preoperative CRT with capecitabine, oxaliplatin, and concurrent radiation followed by surgery and four cycles of postoperative adjuvant capecitabine and oxaliplatin (CAPOX)—or arm B—induction CAPOX followed by CRT and surgery. The primary end point was pathologic complete response rate (pCR). Results: On an intention-to-treat basis, the pCR for arms A and B were 13.5% (95% CI, 5.6% to 25.8%) and 14.3% (95% CI, 6.4% to 26.2%), respectively. There were no statistically significant differences in other end points, including downstaging, tumor regression, and R0 resection. Overall, chemotherapy treatment exposure was higher in arm B than in arm A for both oxaliplatin (P < .0001) and capecitabine (P < .0001). During CRT, grades 3 to 4 adverse events were similar in both arms but were significantly higher in arm A during postoperative adjuvant CT than with induction CT in arm B. There were three deaths in each arm during the treatment period. Conclusion: Compared with postoperative adjuvant CAPOX, induction CAPOX before CRT had similar pCR and complete resection rates. It did achieve more favorable compliance and toxicity profiles. On the basis of these findings, a phase III study to definitively test the induction strategy is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Gérard, J.-P., Conroy, T., Bonnetain, F., Bouché, O., Chapet, O., Closon-Dejardin, M.-T., Untereiner, M., Leduc, B., Francois, É., Maurel, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7629 · Cited by 1,731
Self-citationPathological features of rectal cancer after preoperative radiochemotherapy
Dworak, O., Keilholz, L., & Hoffmann, A. (1997) · International Journal of Colorectal Disease · doi:10.1007/s003840050072 · Cited by 1,338
Randomized phase II clinical trials.
Simon, R. M., Wittes, R. E., & Ellenberg, S. S. (1985) · PubMed · Cited by 482
Chau, I., Brown, G., Cunningham, D., Tait, D., Wotherspoon, A., Norman, A. R., Tebbutt, N., Hill, M., Ross, P. J., Massey, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4875 · Cited by 474
Multicenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer
Rödel, C., Liersch, T., Hermann, R. M., Arnold, D., Reese, T., Hipp, M., Fürst, A., Schwella, N., Bieker, M., Hellmich, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3675 · Cited by 230
Machiels, J.-P., Duck, L., Honhon, B., Coster, B. D., Coche, J.-C., Scalliet, P. G. M., Humblet, Y., Aydın, S., Kerger, J. N., Remouchamps, V. M., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi406 · Cited by 134
Glynne‐Jones, R., Grainger, J., Harrison, M., Ostler, P. J., & Makris, A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602960 · Cited by 115
Aschele, C., Pinto, C., Cordio, S. S., Rosati, G., Tagliagambe, A., Artale, S. A., Rosetti, P., Lonardi, S., Boni, L., Cionini, L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra4008 · Cited by 106
Glynne‐Jones, R., Sebag‐Montefiore, D., Maughan, T., Falk, S., & McDonald, A. C. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj031 · Cited by 83
Aschele, C., Pinto, C., Cordio, S. S., Rosati, G., Tagliagambe, A., Artale, S. A., Rosetti, P., Lonardi, S., Boni, L., & Cionini, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.cra4008 · Cited by 52
Cited by
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., El Dika, I. H., Segal, N., Shcherba, M., Sugarman, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201445 · Cited by 1,625
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Conroy, T., Bosset, J.-F., Etienne, P.-L., Rio, E., François, É., Mesgouez-Nebout, N., Vendrely, V., Artignan, X., Bouché, O., Gargot, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00079-6 · Cited by 1,344
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0061 · Cited by 944
Metadata
- Authors
- Fernández-Martos, C., Pericay, C., Aparicio, J., Salud, A., Safont, M., Massuti, B., Vera, R., Escudero, P., Maurel, J., Marcuello, E., Mengual, J. L., Saigi, E., Estevan, R., Mira, M., Polo, S., Hernandez, A., Gallen, M., Arias, F., Serra, J., & Alonso, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-10
- Volume
- 28
- Issue
- 5
- Pages
- 859-865
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2047778994
- Cited by
- 438
- References
- 14
- FWCI
- 11.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.